## ABIVAX

## ABIVAX announces the publication of its 2016 Registration Document and highlights the development stage of its portfolio

May 11, 2017


Paris, May 11<sup>th</sup>, 2017 at 9:00pm (CEST) – ABIVAX (Euronext Paris: FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to eliminate viral diseases, announced today the publication of its 2016 Registration Document, filed with the French Market Authority (Autorité des Marchés Financiers) on May 11th, 2017 under the registration number: R. 17-043.

The 2016 Annual Financial Report and the preliminary results of the second Phase IIa clinical trial evaluating the effect of ABX464, ABIVAX's drug candidate, in HIV-patients, are namely included in this Registration Document.

Copies of this document are available to the public free of charge upon request at ABIVAX's headquarters – 5, rue de la Baume, 75008 Paris – and online on the Company's website (<u>www.abivax.com</u>) and the AMF website (<u>www.amf-france.org</u>).

The company also highlights below the development stage of its portfolio of compounds generated from its 3 technology platforms:

## ABIVAX: A strong and diversified pipeline



\* The clinical trial has been completed with respect to patient treatment and follow-up. Clinical data have been consolidated and analyzed leading to top line results communication on May 2nd 2017.

\*\* Inflammatory Bowel Disease (IBD)